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1  Introduction 
Heart rhythm disturbances become of special importance 
when patients reach a senior age. Atrial fibrillation (AF) is 
the most prevalent arrhythmia among the old age groups, 
and its impact on morbidity and mortality becomes of para-
mount significance. In this population, AF is responsible for 
significant amount of thromboembolic cerebrovascular 
events, especially for disabling and fatal strokes.[1] Follow-
ing announcement of the special issue of the Journal of Geri-
atric Cardiology devoted to heart rhythm disorders in the 
elderly, a number of submissions have been received with 
AF as the major topic of authors’ researches. 
Here we would like to introduce this special issue, which 
finally included clinical research papers on age-related dif-
ferences in outcomes of AF catheter ablation, AF-related 
stroke hospitalizations, mortality predictors in patients with 
AF, stroke prevention using left atrial appendage (LAA) 
occluder implantation. Additionally, a clinical research paper 
describes predictors of heart rhythm disturbances in patients 
with obstructive sleep apnea and hypertension, and a paper 
describes ventricular tachycardia suppression by renal den-
ervation in patients with left heart thrombosis and contrain-
dications to conventional endocardial substrate modification. 
Having included into the issue two controversial topics of 
special importance, AF catheter ablation and LAA occluder 
implantation in the elderly, we decided to discuss them in 
the light of other recently published studies. 
2  Atrial fibrillation: risk-benefit considera-
tions in elderly patients undergoing catheter 
ablation 
AF ablation safety and efficacy have been evaluated in a 
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number of observational and randomized studies. It had 
been anticipated that age is associated with advanced myo-
cardial fibrosis and an increased extent of arrhythmogenic 
substrate remodeling in both atria.[2,3] However, age-strati-
fied histological evaluation revealed that myocardial fibrosis 
is robustly associated with the presence of AF, without cor-
relation between patient age and changes in atrial tissue.[4] 
According to this latter finding, pulmonary vein isolation in 
elderly patients is thought to be as effective as in younger 
patients. On the other hands, older patients usually have 
more severe co-morbidities, and AF ablation can potentially 
be associated with more procedure-related complications. 
Outcomes of ablation in septuagenarians and octoge-
narians have been evaluated by many groups around the 
world; however, the majority of those studies were sin-
gle-center retrospective analyses, and only a few publica-
tions included data from prospective multicenter registries. 
We have identified 14 papers where age groups were stud-
ied separately, and efficacy and/or safety outcomes were 
clearly reported for patients >65/>75 years old (Table 1). 
Among these studies, 11 included a control group of younger 
patients. Twelve studies reported on 1st AF ablation proce-
dure success (arrhythmia freedom with regular ECG screen-
ing), and 12 studies reported on detailed procedure-related 
major complications, that required additional interventions 
or prolonged hospital stay. 
It was possible to extract data for comparison between 
older and younger age groups from 10 studies: six studies 
demonstrated no difference in efficacy and safety between 
groups;[6,8–11,14] one study showed that complications were 
more frequent in the older group;[15] one study showed that 
success rate was lower in the older group;[18] in one study 
the authors found that older patients had more major com-
plications and poorer success rate of ablation;[16] and in  
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Table 1.  Published analyses evaluating AF ablation efficacy and safety in old patients. 
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Number of old 
patients 
Number of con-
trol patients 
% of 
paroxys-
mal AF
Type of 
ablation
#Major com-
plications, 
n (%) (older/ 
younger 
patients) 
Mean fol-
low-up 
period, 
months 
12-months ar-
rhythmia freedom 
after 1st ablation 
(older patients 
only) 
Arrhythmia 
freedom after 
1st ablation at 
last follow-up
(Older/young
er patients)
Different 
outcome 
compared 
to a younger 
group 
Corrado A,  
et al.[5] 
> 75 
yrs 
174 No 55% RF 5 (2.9%) 20 NA 73% NA 
Zado E,  
et al.[6] 
> 75 
yrs 
32 1472 53% RF 
1 (3.1%)/ 
24 (1.6%) 
24 NA 50%/59.5% No 
Kusumoto F,  
et al.[7] 
> 75 
yrs 
61 179 34% RF 0/2 (1.1%) 12 60% 60%/88% NA 
Tan H,  
et al.[8] 
≥ 80 
yrs* 
49 328 55% RF 
1(2%)/ 
7(2.1%) 
18 NA 70%/73% No 
Bunch TJ,  
et al.[9] 
≥ 80 
yrs 
35 717 45.7% RF NA 12 78% 78%/75% No 
Santangeli P,  
et al.[10] 
≥ 80 
yrs 
103 2651 25% RF 
1 (0.97%)/
25 (0.9%) 
18 NA 69%/71% No 
Lioni L,  
et al.[11] 
> 65 
yrs 
95 225 100% RF 
3 (3.2%)/ 
4 (1.7%) 
34 57.9% 57.9%/67.4% No 
Metzner I,  
et al.[12] 
≥ 75 
yrs 
94 No 59% RF 7 (7%) 37 NA 38% NA 
Pott A,  
et al.[13] 
> 75 
yrs 
40 No 77.5% Cryo 1 (2.5%) 15 86.4% 77.5% NA 
Abugattas JP, 
et al.[14] 
> 75 
yrs 
53 106 100% Cryo 0/2 (1.9%) 13 81.1% 81.1%/84.9% No 
Moser J,  
et al.[15] 
> 75 
yrs 
227 4222 59.9%
RF: 84.6%; 
Cryo: 15.4%
10 (4.4%)/
12 (2.7%) 
15.1 NA NA 
Yes, com- 
plications 
Kautzner  
J, et al.[16] 
> 70 
yrs 
394 2803 66.5% RF 5.3%/3.2% 25 NA 44.2%/58.2%
Yes, com-
plications and 
success 
Kis Z,  
et al.[17] 
> 65 
yrs 
80 310 90% 
RF 39%; 
Cryo 61%
NA 72 NA NA 
No, com-
plications 
Bulava A,  
et al.[18] 
> 80 
yrs 
50 
259 (< 50  
years old) 
42% RF 
2 (4%)/ 
11 (4.2%) 
12 64% 64%/83.8% 
Yes, 
success 
Overall** 
 
> 75 
yrs 
883 for safety 
analysis; 
691 for efficacy 
analysis 
9217 for safety 
analysis; 
5712 for efficacy 
analysis 
54.4%
RF: 80.6%; 
Cryo: 19.4%
28 (3.2%)/
191 (1.9%)
Median 18 
months, IQR
(13.5; 24.75)
72.8% 
65.7%† / 
67.2%‡ 
Complications, 
P = 0.0433;
Success, 
P = 0.42†† 
#Severe procedure-related complications, requiring additional interventions; *Although three groups of patients were studied (1st group ≥ 80 years old, 2nd group 
70–79 years old, 3rd group 60-69 years old), only the 1st group was included into this pooled analysis; **In total, data from 10 studies reporting on complica-
tions in patients > 75 years old was used, and data from 10 studies reporting on success rate in patients > 75 years old; †A value derived from six studies with 
available data; ††Between groups, as reported arrhythmia-free status at last follow-up visit, Chi-square test with two-tailed P; ‡A value derived from 12 studies 
with available data. AF: atrial fibrillation; Cryo: cryoballoon ablation; IQR: interquartile range (first and third quartiles); NA: non-available/not reported data; 
RF: radiofrequency ablation. 
 
one study only complications were reported and there was 
no difference between groups.[17] 
Since there was no common definition of the older age 
group in the studies, we combined data from reports dealing 
with patients > 75 years old. This pooled analysis in 10,100 
subjects (883 patients > 75 years old and 9217 patients < 75 
years) showed that procedure-related major complications 
were more frequently seen in older patients (3.2% vs. 1.9%, 
P = 0.0433). On the other hand, at a median of 18 months, 
the success rate of a single AF ablation procedure, defined 
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as no documented evidence of sustained atrial tachyar-
rhythmia, was not different between the older and younger 
groups (analyzed in 691 subjects >75 years old and in 5712 
controls). Forest plot analyses of AF ablation success and 
procedure-related major complications from comparative 
studies (patients younger and older 75 years, each analysis 
included 7 studies) showed the same results, see Figures 1 
and 2. 
Considering these findings, we strongly believe that when 
symptomatic AF is refractory to antiarrhythmic medications, 
decision on referral of a patient for AF ablation should not 
be restricted to younger patients. However, patients of older 
age should be informed regarding the higher risk of com-
plications. 
3  Left atrial appendage occlusion in elderly 
patients 
Outcomes of interventional LAA occlusion have mainly 
been reported in observational studies and registries, and 
one occluder device has been investigated in comparison 
with oral anticoagulation in randomized trials.[19,20] It has 
been suggested that percutaneous LAA occlusion is 
non-inferior to warfarin treatment regarding prevention of 
stroke and possibly associated with less bleeding events. 
Although the majority of published studies included elderly 
patients with a mean patient age ranging between 70 and 74 
years, there is a lack of studies exclusively investigating 
safety and efficacy of LAA occlusion in patients over 75 
years old. There is one sub-analysis showing higher bleed-
ing events in patients >75 years after LAA occluder im-
plantation compared to a younger group (4.4% vs. 1.4%).[21] 
Oral anticoagulation therapy often remains underutilized 
in elderly AF patients, and adherence to therapy is some-
times a challenge in this subpopulation.[22] This is also ex-
aggerated by the fact that frail patients are also at increased 
risk of stroke and bleeding.[23] Therefore, interventional 
percutaneous LAA occlusion is an attractive strategy in old 
patients, and implantation of this device could obviate the 
need for oral anticoagulation. 
In this special issue of Journal of Geriatric Cardiology 
Davtyan K with co-authors describe their long-term experi-
ence with LAA occlusion in AF patients > 75 years old.[24] 
When these results are presented along with other reports on 
LAA occlusion, it seems that serious complications related 
to the implantation procedure vary from 0 to 5.1%, with a  
 
Figure 1.  Forest plot analysis of AF ablation success in patients aged < 75 and > 75 years. Only seven studies with evaluation of ar-
rhythmia-free rate in patients >75 years old and a control group were included. No heterogeneity analysis was performed, since all studies 
were observational. Statistical analysis and graphical presentation were performed using Excel 2003 SP3 (Microsoft Corporation, USA). AF: 
atrial fibrillation. 
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Figure 2.  Forest plot analysis of major complications related to AF ablation in patients aged < 75 and > 75 years. Only seven studies 
with evaluation of arrhythmia-free rate in patients > 75 years old and a control group were included. No heterogeneity analysis was per-
formed, since all studies were observational. AF: atrial fibrillation. 
mean rate 4.8% (Table 2). Regarding late events, smaller 
studies show a perfect protection from stroke, while a study 
with the largest cohort of old patients reveal 2.3% rate of 
stroke/transient ischaemic attack (TIA) despite successful 
occluder implantation. 
A warning finding among patients with an implanted 
Table 2.  Results of percutaneous LAA occluder device implantation derived from studies reporting outcomes in elderly patients. 
 Gafoor S, et al.[25] Freixa X, et al.[26] Davtyan K, et al.[24] Overall 
Design Retrospective 
Retrospective analysis of 
prospectively collected data
Retrospective 
Number of sites Single-center Multicenter Single-center 
All  
retrospective 
Definition of old patients > 80 yrs > 75 yrs > 75 yrs > 75 yrs 
Control group No Yes (n = 376) Yes (n = 54) 430 
Number of old patients 75 452 18 545 
Mean CHA2DS2-VASC 5.2 5.1 5.27 5.19 
Devices Watchman, ACP, PLAATO, Lariat, Coherex ACP ACP, Watchman  
Follow-up 1 yr 1.4 yrs 4 yrs Median 1.4 yrs
Number of old patients with an implanted 
device and available follow-up data 
75 430 18 523 
Periprocedural complications in old patients    
Total major procedure-related compli-
cations 
3 (3.9%) 23 (5.1%) 0 26 (4.8%) 
Stroke/TIA 1 (1.3%) 3 (0.7%) 0 4 (0.7%) 
Device embolization 0 4 (0.9%) 0 4 (0.7%) 
Major bleeding 1 (1.3%) 6 (1.3%) 0 7 (1.3%) 
Cardiac tamponade 0 10 (2.2%) 0 10 (1.8%) 
Death 0 6 (1.3%) 0 6 (1.1%) 
Late events in old patients     
Stroke/TIA 0 10 (2.3%) 0 10 (1.8%) 
Device thrombus 1 NA 1 NA 
Major bleeding 0 11 (2.6%) 0 11 (2%) 
Death 2 (2.7%) 40 (9.3%) 3 (17%) 45 (8.3%) 
Data are presented as n (%) unless other indicated. LAA: left atrial appendage; NA: non-available/not reported data; TIA: transient ischaemic attack. 
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LAA occluder is a thrombus on the device in the early and 
mid-term follow-up period. Thus, in a recent French multi-
center observational study, which mainly comprised of 453 
older patients (mean age 75 yrs), in whom either the 
Watchman or Amplatzer Amulet (Boston Scientific, USA) 
was implanted, the authors reported thrombus formation in 
24/453 (5.3%) cases.[27] There was no statistical difference 
between two devices. Older age and a previous history of 
ischemic stroke independently predicted thrombus. The 
predictors of stroke/TIA during follow-up were vascular 
diseases (P = 0.002) and thrombus on device (P = 0.008). 
According to the 2016 ESC atrial fibrillation manage-
ment guidelines, LAA occluder implantation has IIb class 
indication for stroke prevention in patients with AF and 
contra-indications for long-term anticoagulant treatment.[1] 
We suggest that safety of LAA occlusion in elderly patients 
is under-investigated and a balance between potential bene-
fit and risk of procedure-related and device-related adverse 
events should be considered in each individual patient. 
In conclusion, we would like to emphasize that although 
there is a lack of systematic and prospective results on AF 
ablation in elderly patients, the existent data shows catheter 
ablation is favorable for the management of symptomatic 
arrhythmia. Efficacy of this procedure in old patients seems 
not significantly different compared to younger patients, but 
the higher risk of major complications should be considered. 
At the same time, we call for more caution when LAA 
occluder implantation is considered in old patients. The 
procedure-related complication rate is considerable in this 
population, and this risk needs to be carefully weighed with 
potential benefit, especially understanding risk of ischemic 
stroke after successful LAA occluder implantation. There is 
no systematic comparison of percutaneous LAA occlusion 
efficacy with non-vitamin K direct oral anticoagulants. 
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